DGX
NYSEQUEST DIAGNOSTICS INC
Healthcare · Services-Medical Laboratories
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$10.8B
2021
$9.9B
2022
$9.3B
2023
$9.9B
2024
$11.0B
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$11.0B
Net Income$1.0B
Gross Profit—
Oper Income$1.6B
EPS (dil)$8.75
Rev/sh$99.69
FCF/sh$12.28
Book/sh$65.10
Gross M—
Oper M14.1%
Profit M9.5%
FCF M12.3%
ROE14.5%
ROA6.4%
ROIC9.1%
R&D/Rev—
Rev Y/Y11.8%
Rev 3Y CAGR3.7%
EPS Y/Y13.8%
EPS 3Y CAGR3.2%
FCF 3Y CAGR1.1%
Payout34%
Div/sh$1.80
Shs Chg Y/Y0%
Current Ratio1.04
Quick Ratio0.96
Debt/Eq0.86
Int Coverage9.6×
Net Debt$5.8B
Total Debt$6.2B
Cash & Eq$420.0M
Total Assets$16.2B
Oper CF$1.9B
Capex$527.0M
Free CF$1.4B
Buybacks$450.0M
Equity$7.2B
Liabilities—
Shs Outstand0.11B
SectorHealthcare
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $10.8B | $9.9B | $9.3B | $9.9B | $11.0B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $2.4B | $1.4B | $1.3B | $1.3B | $1.6B |
| Net Income | $2.1B | $1.0B | $908.0M | $921.0M | $1.0B |
| Diluted EPS | $15.55 | $7.97 | $7.49 | $7.69 | $8.75 |
| Operating Cash Flow | $2.2B | $1.7B | $1.3B | $1.3B | $1.9B |
| Free Cash Flow | $1.8B | $1.3B | $864.0M | $909.0M | $1.4B |
COMMUNITY · $DGX0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.